Skip to main content
SpringerLink
Log in

Myostatin as a potential biomarker to monitor sarcopenia in hip fracture patients undergoing a multidisciplinary rehabilitation and nutritional treatment: a preliminary study

  • Short Communication
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Hip fractures are the most common osteoporotic fractures related to disability in older adults, requiring surgery and a subsequent rehabilitation treatment. Sarcopenia is currently considered as a predictive of worse outcome in hip fracture patients and myostatin has been recently proposed a potential biomarker of this condition. Twenty hip fracture patients after total hip replacement (mean aged 75.9 ± 2.4 years) were randomly divided into two groups of ten subjects (groups A and B). Both groups performed a rehabilitation program (5 sessions of 40 min/week for 2 weeks, followed by home-based exercise protocol). Group A received also 2-month amino acid supplementation. Serum myostatin levels significantly decreased after 2 months in both group A (p = 0.01) and group B (p = 0.03) in sarcopenic patients only in group A (p = 0.04). These results suggest that myostatin might be considered a promising biomarker of sarcopenia in hip fracture older adults’ patients undergoing rehabilitation and amino acid supplementation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Calvani R, Picca A, Marini F et al (2018) The “BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons” (BIOSPHERE) study: rationale, design and methods. Eur J Intern Med 56:19–25

    Article  Google Scholar 

  2. Tarantino U, Capone A, Planta M et al (2010) The incidence of hip, forearm, humeral, ankle, and vertebral fragility fractures in Italy: results from a 3-year multicenter study. Arthritis Res Ther 12:R226

    Article  Google Scholar 

  3. Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31

    Article  Google Scholar 

  4. White TA, LeBrasseur NK (2014) Myostatin and sarcopenia: opportunities and challenges—a mini-review. Gerontology 60:289–293

    Article  CAS  Google Scholar 

  5. Cho TJ, Gerstenfeld LC, Einhorn TA (2002) Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res 17:513–520

    Article  CAS  Google Scholar 

  6. Guo W, Flanagan J, Jasuja R et al (2008) The effects of myostatin on adipogenic differentiation of human bone marrow-derived mesenchymal stem cells are mediated through cross-communication between Smad3 and Wnt/beta-catenin signaling pathways. J Biol Chem 283:9136–9145

    Article  CAS  Google Scholar 

  7. de Souza EO, Tricoli V, Aoki MS et al (2014) Effects of concurrent strength and endurance training on genes related to myostatin signaling pathway and muscle fiber responses. J Strength Cond Res 28:3215–3223

    Article  Google Scholar 

  8. Binns A, Gray M, Henson AC et al (2017) Changes in lean mass and serum myostatin with habitual protein intake and high-velocity resistance training. J Nutr Health Aging 21:1111–1117

    Article  CAS  Google Scholar 

  9. Becker C, Becker C, Lord SR et al (2015) Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol 3:948–957

    Article  CAS  Google Scholar 

  10. Paoli A, Pacelli QF, Neri M et al (2015) Protein supplementation increases postexercise plasma myostatin concentration after 8 weeks of resistance training in young physically active subjects. J Med Food 18:137–143

    Article  CAS  Google Scholar 

  11. Sukkar SG, Gallo F, Borrini C et al (2012) Effects of a new mixture of essential amino acids (Aminotrofic®) in malnourished haemodialysis patients. Med J Nutr Metab 5:259–266

    Article  CAS  Google Scholar 

  12. Iolascon G, Moretti A, de Sire A et al (2018) Pharmacological therapy of sarcopenia: past, present and future. Clin Cases Miner Bone Metab 15:411–419

    Google Scholar 

  13. de Sire A, Invernizzi M, Lippi L et al (2019) Nutritional supplementation in hip fracture sarcopenic patients: a narrative review. Clin Cases Miner Bone Metab. 16:27–30

    Google Scholar 

  14. Invernizzi M, de Sire A, D’Andrea F et al (2019) Effects of essential amino acid supplementation and rehabilitation on functioning in hip fracture patients: a pilot randomized controlled trial. Aging Clin Exp Res 31:1517–1524

    Article  Google Scholar 

  15. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39:412–423

    Article  Google Scholar 

Download references

Funding

The study was not funded.

Author information

Authors and Affiliations

  1. Physical and Rehabilitative Medicine, Department of Health Sciences, University of Eastern Piedmont “A. Avogadro”, Viale Piazza D’Armi, 1, 28100, Novara, Italy

    Alessandro de Sire, Alessio Baricich, Carlo Cisari & Marco Invernizzi

  2. Rehabilitation Unit, “Mons L. Novarese” Hospital, Moncrivello, Vercelli, Italy

    Alessandro de Sire

  3. Physical Medicine and Rehabilitation Unit, University Hospital “Maggiore della Carità”, Novara, Italy

    Alessio Baricich & Carlo Cisari

  4. Innovative Research Laboratory for Wound Healing, Department of Health Sciences, University of Eastern Piedmont “A. Avogadro”, Novara, Italy

    Filippo Renò

  5. Division of Pathology, IEO-European Institute of Oncology IRCCS, University of Milan, Milan, Italy

    Nicola Fusco

Authors
  1. Alessandro de Sire
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessio Baricich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Filippo Renò
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlo Cisari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicola Fusco
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marco Invernizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco Invernizzi.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical statement and Informed consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Sire, A., Baricich, A., Renò, F. et al. Myostatin as a potential biomarker to monitor sarcopenia in hip fracture patients undergoing a multidisciplinary rehabilitation and nutritional treatment: a preliminary study. Aging Clin Exp Res 32, 959–962 (2020). https://doi.org/10.1007/s40520-019-01436-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40520-019-01436-8

Keywords

Search

Navigation